Sign in

    Alana Lelo

    Vice President and Equity Research Associate at Guggenheim

    Alana Lelo, PhD, is a Vice President and Equity Research Associate at Guggenheim Partners, specializing in life sciences and healthcare equity research with a strong focus on bridging complex biomedical science and investment analysis. Leveraging her academic background in tumor biology and prior industry roles at Black Diamond Therapeutics and Cold Spring Harbor Laboratory, she brings scientific depth to financial markets, supporting equity coverage of leading biopharmaceutical and biotechnology companies. Dr. Lelo began her career with research and teaching roles at Georgetown University, followed by pivotal positions in the biotech sector before joining Guggenheim Partners, where she currently advances investment strategies in healthcare. While specific performance metrics and professional registrations are not publicly available, her career reflects a blend of scientific rigor and financial acumen within the equity research domain.

    Alana Lelo's questions to RVNC leadership

    Alana Lelo's questions to RVNC leadership • Q4 2023

    Question

    Asked for details on the patient coupon program and the impact of removing the no advertised price policy (NAPP), including any available metrics.

    Answer

    Mark Foley explained the patient coupon is a $75 discount designed to stimulate trial and experience, with metrics to be shared on the next call. He noted the program has been well-received. The removal of the NAPP has also been positively received, as it allows practices to more actively promote Revance products. While no specific metrics were shared, he stated it aligns with their new strategy and the early response is encouraging.

    Ask Fintool Equity Research AI